NASDAQ:TRAW Traws Pharma (TRAW) Stock Price, News & Analysis $0.86 +0.01 (+0.91%) As of 02:30 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Traws Pharma Stock (NASDAQ:TRAW) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Traws Pharma alerts:Sign Up Key Stats Today's Range$0.81▼$0.8650-Day Range$0.76▼$2.1852-Week Range$0.64▼$3.27Volume78,619 shsAverage Volume1.34 million shsMarket Capitalization$8.72 millionP/E RatioN/ADividend YieldN/APrice Target$1.00Consensus RatingReduce Company Overview Traws Pharma, Inc., a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza. It is also developing narazaciclib, a multi-kinase CDK4/6 inhibitor, which is in Phase 1/2 clinical trials in patients with cancer, with or without co-administration of letrozole to define the recommended phase 2 dose for further development in endometrial cancer; and oral rigosertib, which is administered alone or in combination for investigation in various cancers. The company was formerly known as Onconova Therapeutics, Inc. and changed its name to Traws Pharma, Inc. in April 2024. Traws Pharma, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania. Read More Traws Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks62nd Percentile Overall ScoreTRAW MarketRank™: Traws Pharma scored higher than 62% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingReduce Consensus RatingTraws Pharma has received a consensus rating of Reduce. The company's average rating score is 1.60, and is based on no strong buy ratings, no buy ratings, 3 hold ratings, and 2 sell ratings.Upside PotentialTraws Pharma has a consensus price target of $1.00, representing about 17.6% upside from its current price of $0.85.Amount of Analyst CoverageTraws Pharma has only been the subject of 4 research reports in the past 90 days.Read more about Traws Pharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Traws Pharma are expected to grow in the coming year, from ($1.43) to ($1.27) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Traws Pharma is -0.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Traws Pharma is -0.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Traws Pharma's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted14.65% of the float of Traws Pharma has been sold short.Short Interest Ratio / Days to CoverTraws Pharma has a short interest ratio ("days to cover") of 1.95, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Traws Pharma has recently decreased by 17.73%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTraws Pharma does not currently pay a dividend.Dividend GrowthTraws Pharma does not have a long track record of dividend growth. News and Social Media1.6 / 5News Sentiment-0.39 News SentimentTraws Pharma has a news sentiment score of -0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Traws Pharma this week, compared to 3 articles on an average week.Search InterestOnly 4 people have searched for TRAW on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows7 people have added Traws Pharma to their MarketBeat watchlist in the last 30 days. This is an increase of 600% compared to the previous 30 days. Company Ownership3.2 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $998,207.00 in company stock, which represents 11.5587% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Traws Pharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $998,207.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders7.57% of the stock of Traws Pharma is held by insiders.Percentage Held by Institutions7.95% of the stock of Traws Pharma is held by institutions.Read more about Traws Pharma's insider trading history. Receive TRAW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Traws Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TRAW Stock News HeadlinesTraws Pharma Provides Updated Guidance on Influenza Prophylaxis ProgramJune 22 at 7:00 AM | globenewswire.comQ2 EPS Estimates for Traws Pharma Lifted by HC WainwrightJune 22 at 1:12 AM | americanbankingnews.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.June 22 at 1:00 AM | Porter & Company (Ad)Brokerages Set Traws Pharma, Inc. (NASDAQ:TRAW) Target Price at $8.00June 20 at 4:43 AM | americanbankingnews.comOutlook for Bucks County biotech take another hit with second setback for flu drugJune 15, 2026 | bizjournals.comMicron, Nebius surge premarket; Traws Pharma tumblesJune 15, 2026 | finance.yahoo.comTraws Pharma shares slide after UK regulator postpones influenza studyJune 15, 2026 | msn.comTraws Pharma (NASDAQ:TRAW) Raised to Sell at Wall Street ZenJune 13, 2026 | americanbankingnews.comSee More Headlines TRAW Stock Analysis - Frequently Asked Questions How have TRAW shares performed this year? Traws Pharma's stock was trading at $1.13 at the beginning of 2026. Since then, TRAW stock has decreased by 24.8% and is now trading at $0.85. How were Traws Pharma's earnings last quarter? Traws Pharma, Inc. (NASDAQ:TRAW) released its earnings results on Friday, May, 15th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.92) by $0.39. Read the conference call transcript. When did Traws Pharma IPO? Traws Pharma (TRAW) raised $67 million in an IPO on Thursday, July 25th 2013. The company issued 5,166,667 shares at a price of $12.00-$14.00 per share. How do I buy shares of Traws Pharma? Shares of TRAW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Traws Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Traws Pharma investors own include Clearside Biomedical (CLSD), Evofem Biosciences (EVFM), Palatin Technologies (PTN), Sirius XM (SIRI), Adverum Biotechnologies (ADVM) and Company Calendar Last Earnings5/15/2026Today6/22/2026Next Earnings (Estimated)8/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3w+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 For the last 3 weeks, TRAW's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TRAW Previous SymbolNASDAQ:TRAW CIK1130598 Webwww.onconova.com Phone267-759-3680Fax267-759-3681Employees17Year FoundedN/APrice Target and Rating Average Price Target for Traws Pharma$1.00 High Price Target$1.00 Low Price Target$1.00 Potential Upside/Downside+17.6%Consensus RatingReduce Rating Score (0-4)1.60 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($1.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$9.17 million Net MarginsN/A Pretax Margin-710.83% Return on Equity-913.18% Return on Assets-133.88% Debt Debt-to-Equity RatioN/A Current Ratio0.43 Quick Ratio0.43 Sales & Book Value Annual Sales$2.79 million Price / Sales3.10 Cash Flow$0.77 per share Price / Cash Flow1.11 Book Value($0.07) per share Price / Book-12.14Miscellaneous Outstanding Shares10,160,000Free Float9,388,000Market Cap$8.64 million OptionableNo Data Beta1.45 Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:TRAW) was last updated on 6/22/2026 by MarketBeat.com Staff. From Our PartnersPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredNew Chip takes minutes, not daysGeorge Gilder believes today's AI data centers could become tomorrow's typewriters - replaced by a single wafe...Eagle Publishing | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredBacked By Elon Musk, This Could be the Next Hot IPOWhile attention was on the SpaceX IPO, Elon Musk quietly began backing a new AI startup described as 'the fast...Brownstone Research | SponsoredFinancial AI Can Now “See Ahead” in Price of 2,384 StocksThe same AI technology used to predict heart failure and grid blackouts has been adapted to forecast U.S. stoc...TradeSmith | SponsoredI’m shouting ‘Buy Now’ before this stock soarsIn 2023, Marc Chaikin's system flagged an automotive stock as bearish - and it fell 35% shortly after. Today, ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Traws Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Traws Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
